Florence Chaverneff, Ph.D.

Patients taking common hypertensive medications were not found to be at higher risk for infection with severe SARS-CoV-2 or more likely to have severe complications from COVID-19.

Individuals with vs without status epilepticus were found to have a greater prevalence of cardiovascular risk factors and a higher risk of developing cardiovascular diseases.

ST-segment elevation was observed in a cohort of patients presenting to New York City hospitals with COVID-19.

Treatment of patients with hypertension who are infected with the severe acute respiratory syndrome coronavirus 2 with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers may improve clinical outcomes.

Exercise may bring a wide range of benefits to adult and pediatric patients with Fontan circulation.

Wearable technologies that include digital and automated health, as well as telehealth, are expected to be well integrated into cardiovascular care in the next 5 years.

The Food and Drug Administration approved the 50cc temporary Total Artificial Heart System developed and manufactured by SynCardia Systems, LLC as a bridge to heart transplant for patients who are at imminent risk for death from biventricular failure.

The U.S. Food and Drug Administration is launching on April 25, 2019, its “Remove the Risk” campaign, aimed at promoting the safe disposal of unused opioids.